In the last year, the Top 30 Most Active Venture Capital Firms had their hands in one out of every four deals which amounted to nearly $9 billion in funding, of which the healthcare industry garnered nearly 20%. We’ve already seen that investments within healthcare favor the medical devices and pharmaceuticals industries. In this post, we’ll review the investments by round and then compare the top 30’s activity to the rest of their venture capital industry brethren.
As expected, healthcare seed funding from 2009-2010 was essentially nonexistent (one deal in the past 12 months), but Series A, Series B, and Series C have approximately equal shares of the market, around 26% each. Series A had been building momentum from July 2009 through February 2010, but seems to have lost it over the past quarter. Will it return over the next few months?
When comparing the top 30’s by-round healthcare investment activity to the entire venture market’s investing habits, we found that the most active firms regularly committed more dollars to their healthcare deals. The difference is most striking in Series A activity, where the top 30 median investment was nearly triple that of the entire market. On average, the most active firms committed 164% more dollars than the market.
Note: Small number of data points for Top 30 Seed investments
This report was created with data from CB Insights’ emerging technology insights platform, which offers clarity into emerging tech and new business strategies through tools like:
- Earnings Transcripts Search Engine & Analytics to get an information edge on competitors’ and incumbents’ strategies
- Patent Analytics to see where innovation is happening next
- Company Mosaic Scores to evaluate startup health, based on our National Science Foundation-backed algorithm
- Business Relationships to quickly see a company’s competitors, partners, and more
- Market Sizing Tools to visualize market growth and spot the next big opportunity